Iambic Therapeutics: CFO Secora Michael received 198,700 shares

What happened The filing reports that Secora Michael, CFO and chief corp dev ofcr, received equity awards on Oct 14, 2026: 28,400 restricted stock units (RSUs) and 170,300 derivative RSUs, each reported at $0.

Key details

• Transaction date(s) and price(s): Oct 14, 2026; price reported $0 for both grants.
• Shares received: 28,400 RSUs and 170,300 derivative RSUs (total 198,700 shares).
• Shares owned after the transaction: not stated in the filing.
• Footnotes: F1 — RSUs vest 25% on Sep 10, 2027 and the remainder vests in 12 equal quarterly installments beginning Dec 10, 2027. F2 — 25% of the shares subject to the option vest on Oct 14, 2027 and 1/48th vest monthly thereafter.
• Filing date: Oct 16, 2026 (filed two days after the reported transaction date).

Why it may matter

• These entries are equity awards/grants (not market purchases or sales).
• The filing does not show why the insider traded or why the company acted.